Neumora Therapeutics (NMRA) Net Income towards Common Stockholders (2022 - 2026)

Neumora Therapeutics' Net Income towards Common Stockholders history runs 5 years deep, the most recent figure standing at -$53.5 million for Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders rose 21.38% year-over-year to -$53.5 million in Q1 2026; TTM through Mar 2026 was -$222.3 million, a 13.84% increase from a year earlier, with the FY2025 full-year figure at -$236.9 million, up 2.83% from the prior year.
• Net Income towards Common Stockholders improved to -$53.5 million in Q1 2026 per NMRA's latest filing, from -$59.4 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at -$30.9 million in Q3 2022 and bottomed at -$171.9 million in Q4 2022.
• The 5-year median for Net Income towards Common Stockholders is -$56.8 million (2025), against an average of -$65.0 million.
• Across the five-year window, Net Income towards Common Stockholders plunged 71.69% in 2023 and jumped 45.78% in 2024, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$171.9 million in 2022, then jumped by 36.9% to -$108.5 million in 2023, then surged by 45.78% to -$58.8 million in 2024, then fell by 1.01% to -$59.4 million in 2025, then increased by 10.01% to -$53.5 million in 2026.
• Per Business Quant, the three latest NMRA Net Income towards Common Stockholders figures stand at -$53.5 million (Q1 2026), -$59.4 million (Q4 2025), and -$56.8 million (Q3 2025).